As the three clinical trials progressed over the course of about 8 years, so did techniques in determining desire, says Kingsberg, a reproductive biology and psychology researcher at University Hospitals Case Medical Center in Cleveland, Ohio, and consultant to Sprout Pharmaceuticals, which
bought flibanserin from Boehringer Ingelheim in 2011, and was in turn purchased last week by Valeant Pharmaceuticals.
Valeant Pharmaceuticals International Inc. said on Thursday it would
buy Sprout Pharmaceuticals, whose drug
flibanserin (Addyi) became the first approved treatment for low sexual desire in women, for about $ 1 billion with milestone payments.